January 25, 2013
Verastem Inc. to Begin Developing Novel Mesothelioma Drug
Nothing generates excitement in the cancer community quite like the development of a promising new therapy.
Such developments are especially exciting for mesothelioma patients. With only one FDA-approved mesothelioma drug on the market, more options are desperately needed. And while researchers have found ways to make existing drugs more applicable for mesothelioma treatment, nobody has recently created a new drug specifically for the disease.
Verastem, Inc. - a Massachusetts-based biopharmaceutical company - plans to change that.
'We feel that there is such a large medical need here, with so little approved,' Robert Forrester, Verastem's President and Chief Operating Officer, told Asbestos.com.
They're right about the void, and they're moving quickly to fill it.
Full article: http://www.asbestos.com/news/2013/01/25/verastem-inc-to-begin-developing-novel-mesothelioma-drug/